

At a Glance: Revolutionizing Egypt's healthcare industry



Cleopatra Hospital Group (CHG) is Egypt's largest private hospital group by number of its hospital beds and operating hospitals.

Over the last five years, the Group has **revolutionized the Egyptian healthcare industry by bringing high quality, integrated healthcare solutions** to a growing number of patients across a constantly expanding geographical footprint.

Since inception, we have been able to consistently evolve and adapt to changing market dynamics to remain at the industry's forefront. We have expanded our asset base and product offering, integrated our platform to achieve higher efficiencies, all while putting our patients' and their families' needs first every step of the way.



At a Glance: CHG financial highlights



In 2018, CHG reported solid year-on-year growth in both its top and bottom line, with the Group generating revenue growth from all four of its operating hospitals

In 2019 revenues are **expected to continue delivering strong growth** as the Group's expansion efforts begin to bear fruit over the coming quarters.



EGP **125.2** mn

EBITDA² in 1Q19 with a **30% margin**



EGP **416.0** mn

Consolidated revenues in 1Q19 with **20% growth y-o-y**



31%

Gross profit growth
From EGP 117.3 mn in 1Q18 to EGP
154.2 mn in 1Q19



35%

EBITDA² **growth y-o-y** Recording EGP 125.2 mn in 1Q19



235,544¹

Cases served in 1Q19



个0.1%

y-o-y growth in cases served in 1Q19

² EBITDA, Earnings before Interest, Tax, Depreciation and Amortization adjusted for provisions, impairments, LTIP, acquisitions expenses and excluding contributions from other income.



Cleopatra Investor Presentation 1Q19

¹ Cases served includes number of in-patients, outpatient visits and ER visits.

At a Glance: CHG facilities and staff



Cleopatra Hospital Company, is the largest private hospital group in Egypt and consists of **four operational hospitals all in Cairo**, namely:

Cleopatra Hospital

Cairo Specialized Hospital

Nile Badrawi Hospital

Al Shorouk Hospital

During the last few months, the Group further expanded adding:

Queens Hospital (part of CHG as of March 2019) Al Katib Hospital (pending transfer of operations)



4 (2018) + **2** (2019¹)

Operational hospitals across our platform



2 Polyclinics

East Cairo polyclinic is operational as of February 2019. While West Cairo Polyclinic will kick off before H1 2019



643 (4 hospitals) + 50 (Queens) + 89 (Al Katib¹)

Patient beds including c. 420 wards and 125 ICU beds Plan to reach 1,200 beds



1,000

Consultant Physicians attracted from the top 2 Medical Universities



+2,400


Total medical staff including c. 850 resident doctors and c. 1000 nursing staff

 $^{\mathrm{1}}$ Al Katib hospital acquisition is subject to final closing



Cleopatra Investor Presentation 1Q19

At a Glance: A network of hospitals located strategically across greater Cairo



Note (1): Al Katib hospital acquisition is subject to final closing Note (2): expected to increase to 108 beds post expansion



Clearly Defined Growth Strategy










Key Investment Highlights



directors

enhanced

profitability




synergies

Underserved and under-penetrated market with steady demand growth




Supply Gap in Egyptian Healthcare Industry

Hospital Beds (/1,000 people) | 2017




Healthcare Expenditure per Capita (USD) | 2017



Sources: World bank, Business Monitor International (BMI), CAPMAS, FROST & SULLIVAN






Healthcare Expenditure in Egypt

Public vs. Private Healthcare Expenditure | EGP bn




Healthcare Expenditure Contribution by Payment Channel | %



Sources: CAPMAS, FROST & SULLIVAN




Total value of healthcare insurance premiums | EGP mn




Out of pocket expenditure made up the lion's share of payment, ay 56% of total healthcare expenditure in 2014 Due to pressure from middle income families that desires proper medical coverage from private sector, an increasing trend of health insurance coverage as % of total health expenditures exists in the market

Healthcare Demand in Egypt

Number of Hospital Beds – Public and Private Sectors (2011-2015)



Distribution of healthcare expenditure




Sources: FROST & SULLIVAN




Distribution of healthcare expenditure 38% 40% 62% Public ■ OOP ■ Corporate ■ Insurance ☐ Private Due to the steady fall Insurance and **Greater Cairo** in the number of Corporate spending acquires around 38% of private patient account for beds in the public approximately 60% health services sector, creating of the private decreasing trend of healthcare public sector number expenditure, of beds, demand strengthening the arise for private demand for sector hospital beds healthcare services to account for the in Egypt gap

Lifestyle Disease Profile in Egypt

Hepatitis C Prevalence (000 cases) | 2012



Diabetes Prevalence in the 20-79 Age Group | 2013



Cancer Prevalence in Egypt | 000 cases 69.8 67.5 65.3 63.0 3.3 3.2 3.1 3.0 8.9 8.6 8.3 8.0 8.9 8.6 8.3 8.0 17.7 17.1 16.6 16.0 30.0 31.0 28.0 29.0 2013 2015 2020 2025 □ Liver ■ Breast ☐ Digestive track ■ Brain ■ Lung Total cancer cases in Egypt are Chronic diseases such as Hepatitis C, Diabetes and Obesity have an expected to increase by 50% from above average prevalence in 2013 to 2025. Less than 1% of Egypt, driving the market demand the total IP cases are admitted for CHG's services into public sector


Dialysis and renal failure admissions in public hospitals has increased by 16% p.a. between 2010 to 2013

Orthopedic cases also grew on the back of a 4% p.a. increase in road accidents 3% pa for bone cancer surgeries



Key Investment Highlights







Leading position in a highly fragmented market




Leading Position in a Market with High Barriers to Entry











Top Private Hospitals in Cairo - Existing Number of Beds (2018)








Note (1): No. of beds includes Al Katib hospital which is subject to closing; Note (2): Dar El Fouad and As Salam are owned by one entity, Alameda; Note (3): Andalusia group has 3 hospitals that are all less than 100 beds each, two of which are in Alexandria and 1 in Cairo. Note (2): ELAJ Group targets lower class segments. Note (3): The hospital groups shown above represents the hospitals with the highest number of beds



Key Investment Highlights





Leverage on integrated platform and scale to extract synergies

CHG's Integration model



| | ı | ntegratio | on, O | ptimiz | atior | n of O | perat | ions | | | | | |
|---|---|---------------------------------|-----------------|---|-----------------------|-----------------------------------|---------------------------------|----------------------------------|--|--------------------|--|---|---|
| Institutionalizing the Group | Corporate Governance | Centralized Corporate Office | | Jnified ority Matrix | | ansion | Umbrell Name fo Individua | or Each | Unified Pricir Positionin Strategy | _ | nified Financial Sops & Reporting | Value Creation Plans | |
| Human Resources | Standard Organizational Chart / Matrix Org | Salary Scale Exercise | | / Incentive chemes | | Insurance | Traini Develo Progr | pment | Employee Satisfactio Surveying | n | Profit Share Schemes | Appraisal System | - |
| Supply Chain & Synergies | Group Wide Tenders | Item Unifica | ation | Consuma Unificati | | Stan Wareh | | | cal Capex ss Group | Tend | dication ering And agement | Material Planning | |
| Infrastructure / Technology Upgrade | HIS/ERP System Roll Pa Out | ics System Fa | acelifts | COEs Equippir | | OR enovations | | mechanical grades | ICU Upgr And Exten | | Diagnostics & Auxiliary Units Upgrades | New Cath-labs | |
| Business Development | One Stop Shop | COEs | Drug Formula | | ess Asset eferrals | Doo Engag & Ref | ement | Unified Insurance Corp Dea | Reven Mana | ue Cycle gement | Surgical Packages | Enhancing Case Mix | - |
| Quality | CHG Medical Council | JCI Roadm | пар | Unified So Hospital Ma | | Standa Qualit | | | g & Kitchen grades | | ialty Club eetings | Nurse & Medical Teams Training Programs | - |
| Optimize Capacity and Patient Flow | Centralizing Non- core Functions | Unified Call C | Centre | Unified Integrat Ambulance Protoco | ed e & ER | Utiliz Enhand Acros Segm | ement ss All | Medica | al Tourism | | PD Slot agement | ICU Bed Additions | |

Effect on CHG

Optimize operations and management

Standardize and improve quality

Enhance margins

Stronger bargaining power

Establish Partnerships with leading companies

Attract high qualified medical staff

Establish Centers of Excellence


Shared cost benefits

Improve collection / billing



Key Investment Highlights






Solid financial performance with potential for enhanced profitability





Solid Financial Performance




While Cleopatra hospital remains the main revenue contributor to the group, the rest of the group hospitals progressed with growth in the overall group revenues, gross profit and EBITDA














Key Revenue Drivers




Revenue from inpatient admissions and outpatient visits have demonstrated growth y-o-y, at 22% and 4% respectively












Key Revenue Drivers




Driven by surgeries and ER visits, and increasing revenue per visit of 23% and 12% respectively, revenues from each of the mentioned segments have witnessed a notable growth











Key Revenue Drivers





Revenue per bed at group hospitals have demonstrated growth as a result of better utilization and case mix strategy.














Key Investment Highlights







Strong management team with experienced board of directors

Matrix Organizational Structure




CHG has adopted a matrix organizational structure optimizing its operations and managing the employees effectively. The group has appointed the following directors:





Expansion strategy










Feeder network started by the first 2 polyclinics to present in East and West Cairo

Polyclinics act as feeder networks for patient referral for the group hospitals. Specialized across different specialties including internal medicine, dentistry, radiology, ENT, cardiology, orthopedic, gynecology and procedures room







Feeder networks expansion in 2019 compose of two polyclinics (East and West Cairo). East Cairo Polyclinic is operational as of February 2019 while West Cairo Polyclinic is expected to start operating before H2 2019



Feeder network started by the first 2 polyclinics to present in East and West Cairo






5th settlement (East Cairo) Polyclinic operational as of February 2019



Expansion strategy





Building Additional Capacities in Existing facilities



New extension for Al- Shorouk hospital





Al Shorouk hospital expansion

In Q2 2018, the group signed Vital Konzept, a leading Engineering & Consultancy Firm to start the process of Drawings for the extension in preparation for releasing the project for tendering with expected timeline of completion 18 months.

The renovation and capacity increase is expected to

Add 40 beds to the hospital capacity

Total renovation of existing facility


Facelift development for the facility





Expansion strategy





Operating Hospitals



Strategic Acquisitions of Operating Hospitals









El Katib Hospital (Dokki, Giza)(1)

During September 2017, CHG signed definitive agreements to acquire the real estate assets and the operational assets of a new hospital in West Cairo





89 Hospital Beds

Kidney Specialist offering a complementary service

The hospital is also undergoing an additional expansion in order to reach 108 beds, as is expected to contribute around EGP 35mn⁽²⁾ of EBITDA to CHG over the coming period

Status: : OGM Approved Real-estate acquisition , Real-Estate fully acquired as of December 2018 pending completion of business transfer agreement with current operators.

Note (1): This total acquisition and transfer of operations is still pending the completion of certain condition precedents

Note (2): Based on management accounts, and is to subject to diligence and audit, and involve a number of risks, uncertainties and assumptions that could cause actual results and performance to differ materially



Strategic Acquisitions of Operating Hospitals





Queens Hospital (Heliopolis, East Cairo)

Given OGM approval, CHG has finalized and started operating Queens hospital as of March 2019 50 Hospital Beds in Heliopolis (Segment A area) Hospital current focus is on gynecology and pediatrics specialties.

CHG plans to expand its services to include other general services and a Cardiology COE Expected to contribute around EGP 7-10mn (1) of EBITDA to CHG over the coming period Cleopatra staff has started handover of operations and implementing business plan for 2019




Note (1): Based on management accounts, and is to subject to diligence and audit, and involve a number of risks, uncertainties and assumptions that could cause actual results and performance to differ materially



Cleopatra Investor Presentation 1Q19

Expansion strategy





CHG is working on expansions in brownfield hospitals and outside of Cairo



The group is currently assessing and shortlisting potential Brownfield acquisitions in areas where the group does not have presence or in areas that are underserved.

Potential hospital is named "
New Cairo brownfield hospital "
and is expected to operate at
Cleopatra segment with the
following capacities:



21,000 sqm BUA



200 bed capacity



7 operating room



Cath lab



20 Outpatient clinics

Expanding reach beyond greater Cairo

In Bani Suef
governorate (Upper
Egypt) an
underserved
governorate with
one of the lowest
healthcare service
quality provided in
Egypt

CHG entered into a JV with Taaleem (Al Nahda Universities) to complete and finish a 200 bed hospital in Upper Egypt Footprint expansion to Upper Egypt and tapping into a different segment of patients through a low cost model teaching hospital

Status



Hospital Facility Leased



Capex Budget Finalized




Business Plan Completed



Expansion strategy





Creating Strategic entities to serve Group's scale of operations

Strategic initiatives and entities created by CHG to enhance efficiencies in operation

As part of the group's strategy to leverage synergies and expand its service offerings, CHG is now in the process of creating business operation entities:



Cleopatra entity for importing consumables

Aims to serve groups scale of consumables and medical devices demand and create further efficiencies in group purchasing



Pharmaceutical management entity

Aims to serve groups pharmacies and pharmaceutical needs either at Polyclinics or at across different hospitals



Cleopatra Academy for Training

The academy starts by supporting the National Health Insurance program by providing trainings for the public sector





CHG is lead by a Diversified and Experienced Board of Directors



Healthcare Experts



Dr. Mohamed Awad Tag El DinFormer Minister of
Health



Dr. Ahmed EzzeldinExecutive Member &
Group CEO



Dr. Tarek ZahedNon-Executive
Chairman



Sameh Mohsen Founder / Previous CEO Cleopatra Hospital

Active Board Committees

Audit
Nabil Kamhawy,
Chairman

Remuneration

Ahmed Badreldin,

Chairman

Medical Ethics &
Quality
Dr. Mohamed Awad
Tag El Din, Chairman

Financial and Investment Experts



Tarek KabilFormer Minister of
Trade and Industry



Omar Ezz Al Arab Care Healthcare



Nabil Kamhawy Former Head of Ernst & Young Egypt



Samia El Baroudy
Care Healthcare



Ahmed Badreldin Vice Chairman Care Healthcare



Lobna El Dessouky
Director




General Omar Kinawy Former Deputy Head of Intelligence

Key Investor Information



Cleopatra Hospitals Company's Shareholder Structure



Care Health Limited's Key Shareholders



DEG, the German Investment and Development Corporation, is a subsidiary of KFW, aiming at promoting business initiative in developing and emerging market countries as a contribution to sustainable growth and improved living conditions of the local population




A Development Financial
Institution partly owned by
Agence Française de
Développement (AFD), which
promotes private investment
in developing countries to
reach the Millennium
Development Goals



An international financial institution, which uses investment as a tool to build market economies, supporting the development in 30 countries from central Europe to central Asia

Cleopatra Hospitals Company Stock Performance



Note: CLHO share price and volumes has been adjusted from 1 June 17 till 1 November 17 to reflect the change in the share price post the rights issue



Cleopatra Investor Presentation 1Q19



Consolidated Income Statement



| All figures in EGP mn | 1Q2019 | 1Q2018 | % change | FY2018 | FY2017 | % change |
|-----------------------------------|---------|---------|----------|---------|---------|----------|
| | | | | | | |
| Revenues | 416.0 | 347.2 | 20% | 1456.1 | 1126.8 | 29% |
| Cost of sales | (261.8) | (229.8) | 14% | (942.5) | (788.2) | 20% |
| Gross profit | 154.2 | 117.3 | 31% | 513.6 | 338.6 | 52% |
| Gross Profit Margin | 37% | 34% | | 35% | 30% | |
| General & administrative expenses | (97.6) | (54.4) | 80% | (180.4) | (161.4) | 12% |
| Cost of acquisition activities | (0.5) | (2.6) | -80% | (4.6) | (5.3) | -14% |
| Provisions | (2.7) | (6.2) | -57% | (17.2) | (7.1) | 143% |
| Other income | 1.0 | 3.0 | -67% | 5.2 | 5.5 | -5% |
| EBIT | 54.3 | 57.2 | -5% | 316.6 | 170.3 | 86% |
| EBIT Margin | 13% | 16% | | 22% | 15% | |
| Interest income | 29.4 | 30.1 | -2% | 129.3 | 59.4 | 118% |
| Interest expense | (3.2) | (12.0) | -74% | (38.0) | (74.4) | -49% |
| Profit before tax | 80.6 | 75.3 | 7% | 408.0 | 155.4 | 163% |
| PBT Margin | 19% | 22% | | 28% | 14% | |
| Income tax | (26.3) | (19.5) | 35% | (90.4) | (32.7) | 177% |
| Deferred tax | 0.9 | 1.4 | -35% | (2.4) | (4.4) | -45% |
| Net profit after tax | 55.1 | 57.2 | -4% | 315.2 | 118.2 | 167% |
| Net Profit Margin | 13% | 16% | | 22% | 10% | |
| Distributed as follows: | | | | | | |
| Shareholders of the company | 53.5 | 53.3 | 0% | 210.9 | 76 | 177% |
| Minority rights | 1.6 | 3.9 | -58% | 14.1 | 8.6 | 64% |
| Profit for the period | 55.1 | 57.2 | -4% | 225.0 | 84.6 | 166% |



Consolidated Balance Sheet



| All figures in EGP mn | 31 March 2019 | 31 March 2018 |
|---|---------------|---------------|
| | | |
| Non-current assets | | |
| Fixed assets | 618.2 | 560.5 |
| Intangible assets | 255.1 | 241.0 |
| Payment under investment | 143.9 | 143.9 |
| Total non-current assets | 1,017.2 | 945.4 |
| Current assets | | |
| Inventory | 48.1 | 40.8 |
| Accounts receivables | 317.4 | 302.8 |
| Other receivables and debit balances | 70.7 | 48.5 |
| Due from related parties | 11.6 | 7.1 |
| Cash | 813.0 | 953.4 |
| Total current assets | 1,260.7 | 1,352.5 |
| Total assets | 2,278.0 | 2,298.0 |
| Equity | | |
| Share capital | 800.0 | 800.0 |
| Reserves | 274.2 | 274.2 |
| Retained earnings | 583.3 | 529.8 |
| Equity attributable to the parent company | 1,657.5 | 1,604.0 |
| Non-controlling interest | 76.4 | 74.7 |
| Total equity | 1,733.9 | 1,678.7 |
| Non-current liabilities | | |
| Long term debt – non-current portion | | 67.9 |
| Long term incentive plan | 67.6 | 45.2 |
| Deferred tax liability | 66.0 | 66.9 |
| Total non-current liabilities | 133.6 | 180.0 |
| Current liabilities | | |
| Provisions | 25.4 | 24.9 |
| Creditors and other credit balances | 335.6 | 317.7 |
| CPLTD | 11.6 | 27.2 |
| - | | |
| Current income tax | 38.0 | 69.4 |
| Total current liabilities | 410.6 | 439.3 |
| Total liabilities | 544.1 | 619.3 |
| Total liabilities & shareholders' equity | 2,278.0 | 2,298.0 |



Consolidated Cash Flow Statement




| All figures in EGP mn | 31 March 2018 | 31 March 2019 |
|---|---------------|---------------|
| Cash flow from operating activities: | | |
| Profit before tax | 75.3 | 80.6 |
| Adjustments for: | | |
| Depreciation | 10.4 | 14.0 |
| Amortization of intangible assets | - | - |
| Allowance for impairments of current assets | 6.9 | 31.9 |
| Provisions | 5.0 | 0.5 |
| Capital gain (loss) | (0.1) | (0.2) |
| Credit/Debit interest | (18.2) | (27.3) |
| Changes in current tax liability | - | (57.7) |
| Fixed assets write off | - | - |
| Share-based payments financial liabilities | 10.3 | 22.3 |
| Operating profits before changes in working capital | 89.6 | 64.0 |
| Changes in working capital: | | |
| Change in inventory | (5.7) | (6.2) |
| Change in trade receivables, debtors and other debit balances | (50.8) | (63.7) |
| Change in due from related parties | (4.9) | (4.5) |
| Change in trade payables and other credit balances | 16.7 | 30.2 |
| Net cash flow from operating activities | 44.9 | 19.8 |
| Cash flow from investment activities: | | |
| Proceeds from sale of fixed assets | 0.1 | 0.5 |
| Payments for purchase of fixed assets | (11.7) | (13.8) |
| PUC purchased | (8.5) | (49.6) |
| Advanced payments for purchase of fixed assets | (6.1) | (2.7) |
| Payments for acquisition of a subsidiary, net cash acquired | - | (25.0) |
| Payments under investment | (108.0) | - |
| Credit interest collected | 30.3 | 28.4 |
| Time deposits with maturity more than 3 months | 11.0 | - |
| Net cash flow from investment activities | (92.9) | (62.2) |
| Cash flow from financing activities: | | |
| Dividends paid | (20.0) | (0.0) |
| Proceeds from borrowings | - | - |
| Repayment of borrowings | (126.3) | (95.1) |
| Cash proceed from overdraft | 23.3 | 27.6 |
| Cash paid to overdraft | (22.5) | (16.0) |
| Interest paid | (25.4) | (14.5) |
| Net cash flow from financing activities | 529.1 | (98.0) |
| Net change in cash & cash equivalents during the period | 481.1 | (140.4) |
| Cash & cash equivalents at the beginning of the period | 44.4 | 953.4 |
| Cash & cash equivalents at the end of the period | 525.4 | 813.0 |



Led by an experienced Management Team with Clear Organizational Structure

Strong matrix organizational structure is being implemented at CHG to smooth and improve operations efficiency





Thank you

INVESTOR RELATIONS CONTACTS

Telephone: +2 02 23103771 E-mail: <u>ir@cleopatrahospitals..com</u> <u>investors.cleopatrahospitals.com</u> SHARE HOLDER INFORMATION

EGX: CLHO.CA Listed: June 2016

Shares Outstanding: 1.6 billion



CLEOPATRA HOSPITALS

